{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:11:18Z","timestamp":1792440678544,"version":"4.5.0"},"reference-count":84,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Caspofungin, the first FDA-approved echinocandin antifungal agent, plays a vital role in managing invasive fungal infections (IFIs). Despite its established efficacy, large-scale real-world safety evaluations remain limited. This study provides a comprehensive pharmacovigilance analysis of caspofungin\u2019s safety profile.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Adverse drug events (ADEs) associated with caspofungin were extracted from the FDA Adverse Event Reporting System (FAERS), the Japanese Adverse Drug Event Reporting Database and the Canadian Vigilance Adverse Reaction Database (CVARD) databases. Signal detection utilized four methods: reporting odds ratio proportional reporting ratio Bayesian confidence propagation neural network and multiple gamma-Poisson shrinkage Time-to-onset (TTO) analysis was conducted using FDA Adverse Event Reporting System data, and network pharmacology approaches were employed to investigate potential molecular mechanisms, particularly in caspofungin-related liver injury.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 2,270, 161, and 128 ADE reports were retrieved from FAERS, JADER, and CVARD, respectively. \u201cHepatobiliary disorders\u201d and \u201cinfections and infestations\u201d are overlapping positive signals from three databases at the system organ class level. ADEs such as hypokalemia, sepsis, and drug ineffectiveness were consistent with the drug label. Unexpected signals included prolonged QT interval, cardiac arrest, septic shock, and cholestasis. Cross-database overlap included \u201cdrug ineffective\u201d and \u201ctoxic skin eruption\u201d between FAERS and JADER, and \u201crenal failure,\u201d \u201cphotodermatitis\u201d between FAERS and CVARD. TTO analysis revealed that 89.95% of ADEs occurred within the first month, with a median onset time of 6 days. Network pharmacology identified PI3K\/Akt and HIF-1 pathways as mechanisms underlying caspofungin-induced liver injury.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study highlights both expected and unexpected ADEs of caspofungin, emphasizing the importance of clinical vigilance and molecular research to enhance patient safety and therapeutic outcomes.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1632488","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T05:35:50Z","timestamp":1755063350000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Unveiling the hidden risk of caspofungin: insights from three adverse event reporting systems and network pharmacology integration"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhengfu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e0144337","DOI":"10.1371\/journal.pone.0144337","article-title":"Adverse effects of cholinesterase inhibitors in dementia, according to the pharmacovigilance databases of the United-States and Canada","volume":"10","author":"Ali","year":"2015","journal-title":"PLoS One"},{"key":"B2","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3390\/antibiotics9120877","article-title":"Drug-Resistant fungi: an emerging challenge threatening our limited antifungal armamentarium","volume":"9","author":"Arastehfar","year":"2020","journal-title":"Antibiot. (Basel)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"342","DOI":"10.4103\/0976-500x.103697","article-title":"Complete heart block in a neutropenic patient with aspergillosis: an unusual adverse effect of caspofungins","volume":"3","author":"Biswal","year":"2012","journal-title":"J. Pharmacol. Pharmacother."},{"key":"B4","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s00436-003-0943-1","article-title":"Preliminary study on sex-related inflammatory reactions in mice infected with Schistosoma mansoni","volume":"91","author":"Boissier","year":"2003","journal-title":"Parasitol. Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1521726","DOI":"10.3389\/fphar.2024.1521726","article-title":"Real-world pharmacovigilance of ofatumumab in multiple sclerosis: a comprehensive FAERS data analysis","volume":"15","author":"Chen","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1495137","DOI":"10.3389\/fimmu.2024.1495137","article-title":"Ocular adverse events associated with antibody-drug conjugates: a comprehensive pharmacovigilance analysis","volume":"15","author":"Chen","year":"2024","journal-title":"Front. Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1093\/jac\/dkx480","article-title":"A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009-17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance","volume":"73","author":"Chowdhary","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e313","DOI":"10.1111\/jdv.17808","article-title":"Calcinosis cutis in epidermal necrolysis: role of caspofungin?","volume":"36","author":"Colboc","year":"2022","journal-title":"J. Eur. Acad. Dermatol Venereol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"5656","DOI":"10.3390\/ijms24065656","article-title":"Zebrafish as a model of cardiac pathology and toxicity: spotlight on uremic toxins","volume":"24","author":"Coppola","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"W357","DOI":"10.1093\/nar\/gkz382","article-title":"SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules","volume":"47","author":"Daina","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12911-017-0565-7","article-title":"Adverse events recording in electronic health record systems in primary care","volume":"17","author":"De Hoon","year":"2017","journal-title":"BMC Med. Inf. Decis. Mak."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e428","DOI":"10.1016\/s1473-3099(23)00692-8","article-title":"Global incidence and mortality of severe fungal disease","volume":"24","author":"Denning","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s12012-020-09599-x","article-title":"Caspofungin effects on electrocardiogram of mice: an evaluation of cardiac safety","volume":"21","author":"De Paula","year":"2021","journal-title":"Cardiovasc Toxicol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/s2213-2600(15)00427-0","article-title":"The microbiome and critical illness","volume":"4","author":"Dickson","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1093\/jpids\/piaa119","article-title":"A randomized trial of Caspofungin vs triazoles prophylaxis for invasive fungal disease in pediatric allogeneic hematopoietic cell transplant","volume":"10","author":"Dvorak","year":"2021","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"B17","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/myc.13449","article-title":"Let's talk about sex characteristics-As a risk factor for invasive fungal diseases","volume":"65","author":"Egger","year":"2022","journal-title":"Mycoses"},{"key":"B18","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/j.1365-2710.2007.00812.x","article-title":"Inherited long QT syndrome revealed by antifungals drug-drug interaction","volume":"32","author":"Eiden","year":"2007","journal-title":"J. Clin. Pharm. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12920-017-0246-5","article-title":"Whole genome sequencing of one complex pedigree illustrates challenges with genomic medicine","volume":"10","author":"Fang","year":"2017","journal-title":"BMC Med. Genomics"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1001\/jama.2019.15702","article-title":"Effect of Caspofungin vs fluconazole prophylaxis on invasive fungal disease among children and young adults with acute myeloid leukemia: a randomized clinical trial","volume":"322","author":"Fisher","year":"2019","journal-title":"JAMA"},{"key":"B21","doi-asserted-by":"publisher","first-page":"568","DOI":"10.3390\/antibiotics9090568","article-title":"Antifungal resistance in candida auris: molecular determinants","volume":"9","author":"Fr\u00edas-De-Le\u00f3n","year":"2020","journal-title":"Antibiot. (Basel)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.idc.2023.05.001","article-title":"Emerging diagnostics and therapeutics for invasive fungal infections","volume":"37","author":"Friedman","year":"2023","journal-title":"Infect. Dis. Clin. North Am."},{"key":"B23","doi-asserted-by":"publisher","first-page":"116278","DOI":"10.1016\/j.ecoenv.2024.116278","article-title":"Integrated network toxicology, molecular docking, and in vivo experiments to elucidate molecular mechanism of aflatoxin B1 hepatotoxicity","volume":"275","author":"Ge","year":"2024","journal-title":"Ecotoxicol. Environ. Saf."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.3390\/cancers17132184","article-title":"Caspofungin for primary antifungal prophylaxis in acute myeloid leukemia: a real-life study from an academic center","volume":"17","author":"Grimaldi","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/cr.2010.183","article-title":"NF-\u03baB and STAT3 - key players in liver inflammation and cancer","volume":"21","author":"He","year":"2011","journal-title":"Cell Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1038\/s41598-025-86976-y","article-title":"A real-world pharmacovigilance study of brodalumab based on the FDA adverse event reporting system","volume":"15","author":"He","year":"2025","journal-title":"Sci. Rep."},{"key":"B27","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.annder.2009.10.179","article-title":"Porphyria cutanea tarda revealed by voriconazole","volume":"137","author":"Hickman","year":"2010","journal-title":"Ann. Dermatol Venereol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1186\/s13054-024-05117-5","article-title":"Rezafungin versus caspofungin for patients with candidaemia or invasive candidiasis in the intensive care unit: pooled analyses of the ReSTORE and STRIVE randomised trials","volume":"28","author":"Honor\u00e9","year":"2024","journal-title":"Crit. Care"},{"key":"B29","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jconrel.2024.01.040","article-title":"Development of an environmentally sensitive fluorescent peptide probe for MrgX2 and application in ligand screening of peptide antibiotics","volume":"367","author":"Hou","year":"2024","journal-title":"J. Control Release"},{"key":"B30","doi-asserted-by":"publisher","first-page":"19816","DOI":"10.1021\/acsomega.3c08134","article-title":"Effect of conformational variability on the drug resistance of Candida auris ERG11p and FKS1","volume":"9","author":"Izumi","year":"2024","journal-title":"ACS Omega"},{"key":"B31","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/bcp.15193","article-title":"Pharmacovigilance in low- and middle-income countries: a review with particular focus on Africa","volume":"89","author":"Kiguba","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"12873","DOI":"10.1021\/acs.joc.4c01305","article-title":"Photosensitized oxidative damage from a new perspective: the influence of before-light and after-light reaction conditions","volume":"89","author":"Lapoot","year":"2024","journal-title":"J. Org. Chem."},{"key":"B34","doi-asserted-by":"publisher","first-page":"644","DOI":"10.2105\/ajph.66.7.644","article-title":"Drug prescribing in hospitals: an international comparison","volume":"66","author":"Lawson","year":"1976","journal-title":"Am. J. Public Health"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1345\/aph.1p053","article-title":"Caspofungin-induced severe toxic epidermal necrolysis","volume":"44","author":"Lee","year":"2010","journal-title":"Ann. Pharmacother."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e5694","DOI":"10.1002\/pds.5694","article-title":"MetaLAB-HOI: template standardization of health outcomes enable massive and accurate detection of adverse drug reactions from electronic health records","volume":"33","author":"Lee","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B37","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41375-022-01768-x","article-title":"Invasive fungal diseases impact on outcome of childhood ALL - an analysis of the international trial AIEOP-BFM ALL 2009","volume":"37","author":"Lehrnbecher","year":"2023","journal-title":"Leukemia"},{"key":"B38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1471-2288-14-17","article-title":"Estimating time-to-onset of adverse drug reactions from spontaneous reporting databases","volume":"14","author":"Leroy","year":"2014","journal-title":"BMC Med. Res. Methodol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1259611","DOI":"10.3389\/fphar.2023.1259611","article-title":"Drug-induced QT prolongation and torsade de pointes: a real-world pharmacovigilance study using the FDA adverse event reporting system database","volume":"14","author":"Li","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1485190","DOI":"10.3389\/fphar.2024.1485190","article-title":"A real-world pharmacovigilance analysis of adverse events associated with irbesartan using the FAERS and JADER databases","volume":"15","author":"Liu","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.3389\/fmicb.2020.01027","article-title":"Combination of antifungal drugs and protease inhibitors prevent Candida albicans biofilm formation and disrupt mature biofilms","volume":"11","author":"Lohse","year":"2020","journal-title":"Front. Microbiol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1128\/aac.01128-10","article-title":"Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients","volume":"55","author":"Lortholary","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"B43","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1046\/j.1469-0691.2002.00375.x","article-title":"Influence of gender and age on course of infection and cytokine responses in mice with disseminated Cryptococcus neoformans infection","volume":"8","author":"Lortholary","year":"2002","journal-title":"Clin. Microbiol. Infect."},{"key":"B44","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1007\/s00134-017-4743-y","article-title":"The risk and clinical outcome of candidemia depending on underlying malignancy","volume":"43","author":"Lortholary","year":"2017","journal-title":"Intensive Care Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1001\/jamadermatol.2020.2571","article-title":"Association of age, sex, race, and geographic region with variation of the ratio of basal cell to cutaneous squamous cell carcinomas in the United States","volume":"156","author":"Lukowiak","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1186\/s12913-021-07260-z","article-title":"Pragmatic pharmacoeconomic analyses by using post-market adverse drug reaction reports: an illustration using infliximab, adalimumab, and the Canada vigilance adverse reaction database","volume":"21","author":"Maity","year":"2021","journal-title":"BMC Health Serv. Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"111509","DOI":"10.1016\/j.jclinane.2024.111509","article-title":"A pharmacovigilance study of FDA adverse events for sugammadex","volume":"97","author":"Mao","year":"2024","journal-title":"J. Clin. Anesth."},{"key":"B49","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1165\/rcmb.2020-0492oc","article-title":"Hepatocyte HIF-1 and intermittent hypoxia independently impact liver fibrosis in murine nonalcoholic fatty liver disease","volume":"65","author":"Mesarwi","year":"2021","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/nejmoa021585","article-title":"Comparison of caspofungin and amphotericin B for invasive candidiasis","volume":"347","author":"Mora-Duarte","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s12185-008-0246-5","article-title":"Micafungin-induced immune hemolysis attacks","volume":"89","author":"Nanri","year":"2009","journal-title":"Int. J. Hematol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1177\/0018578719882323","article-title":"Existence of notoriety bias in FDA adverse event reporting system database and its impact on signal strength","volume":"56","author":"Neha","year":"2021","journal-title":"Hosp. Pharm."},{"key":"B53","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.idc.2015.10.012","article-title":"Antifungal agents: spectrum of activity, pharmacology, and clinical indications","volume":"30","author":"Nett","year":"2016","journal-title":"Infect. Dis. Clin. North Am."},{"key":"B54","doi-asserted-by":"publisher","first-page":"W26","DOI":"10.1093\/nar\/gku477","article-title":"SuperPred: update on drug classification and target prediction","volume":"42","author":"Nickel","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.2147\/dddt.s81998","article-title":"Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases","volume":"9","author":"Nomura","year":"2015","journal-title":"Drug Des. Devel Ther."},{"key":"B56","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12906-024-04428-y","article-title":"Analysis of drug-induced interstitial lung disease caused by herbal medicine using the Japanese adverse drug event report database","volume":"24","author":"Oura","year":"2024","journal-title":"BMC Complement. Med. Ther."},{"key":"B57","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"B58","doi-asserted-by":"publisher","first-page":"baq020","DOI":"10.1093\/database\/baq020","article-title":"GeneCards version 3: the human gene integrator","volume":"2010","author":"Safran","year":"2010","journal-title":"Database (Oxford)"},{"key":"B59","doi-asserted-by":"publisher","first-page":"8851","DOI":"10.3390\/ijerph17238851","article-title":"Factors contributing to sex differences in mice inhaling Aspergillus fumigatus","volume":"17","author":"Schaefer","year":"2020","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"B60","doi-asserted-by":"publisher","first-page":"e0165221","DOI":"10.1128\/aac.01652-21","article-title":"Impact of FKS1 genotype on echinocandin in vitro susceptibility in Candida auris and in vivo response in a murine model of infection","volume":"66","author":"Sharma","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"B61","doi-asserted-by":"publisher","first-page":"13286","DOI":"10.1038\/ncomms13286","article-title":"The antifungal caspofungin increases fluoroquinolone activity against Staphylococcus aureus biofilms by inhibiting N-acetylglucosamine transferase","volume":"7","author":"Siala","year":"2016","journal-title":"Nat. Commun."},{"key":"B62","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/s0140-6736(22)02324-8","article-title":"Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial","volume":"401","author":"Thompson","year":"2023","journal-title":"Lancet"},{"key":"B63","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/s1473-3099(23)00551-0","article-title":"Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials","volume":"24","author":"Thompson","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"B64","doi-asserted-by":"publisher","first-page":"2377584","DOI":"10.1080\/22221751.2024.2377584","article-title":"Evolutionary accumulation of FKS1 mutations from clinical echinocandin-resistant Candida auris","volume":"13","author":"Tian","year":"2024","journal-title":"Emerg. Microbes Infect."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1080\/14740338.2021.1922667","article-title":"Antifungal agents and the kidney: pharmacokinetics, clinical nephrotoxicity, and interactions","volume":"20","author":"Tragiannidis","year":"2021","journal-title":"Expert Opin. Drug Saf."},{"key":"B66","doi-asserted-by":"publisher","first-page":"e01582-16","DOI":"10.1128\/aac.01582-16","article-title":"Low caspofungin exposure in patients in intensive care units","volume":"61","author":"van der Elst","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B67","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"Van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B68","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1186\/s12879-018-3333-0","article-title":"Retrospective cohort study comparing the risk of severe hepatotoxicity in hospitalized patients treated with echinocandins for invasive candidiasis in the presence of confounding by indication","volume":"18","author":"Vekeman","year":"2018","journal-title":"BMC Infect. Dis."},{"key":"B69","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.humimm.2004.02.021","article-title":"Predominant type 1 CMV-specific memory T-helper response in humans: evidence for gender differences in cytokine secretion","volume":"65","author":"Villacres","year":"2004","journal-title":"Hum. Immunol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1128\/aac.01657-09","article-title":"Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection","volume":"54","author":"Wang","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"B71","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/nm.4290","article-title":"Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates","volume":"23","author":"Wang","year":"2017","journal-title":"Nat. Med."},{"key":"B72","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.jad.2024.07.034","article-title":"Clinical safety of daridorexant in insomnia treatment: analysis of FDA adverse event reports","volume":"362","author":"Wang","year":"2024","journal-title":"J. Affect Disord."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1619517","DOI":"10.3389\/fphar.2025.1619517","article-title":"An integrated approach based on FDA adverse event reporting system, network pharmacology, molecular docking, and molecular dynamics simulation analysis to study the cardiac adverse reactions and mechanism of action of osimertinib","volume":"16","author":"Wang","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1382441","DOI":"10.3389\/fphar.2024.1382441","article-title":"Assessing the safety of bedaquiline: insight from adverse event reporting system analysis","volume":"15","author":"Wu","year":"","journal-title":"Front. Pharmacol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1080\/14740338.2023.2296966","article-title":"Safety of daratumumab in the real-world: a pharmacovigilance study based on FAERS database","volume":"23","author":"Wu","year":"","journal-title":"Expert Opin. Drug Saf."},{"key":"B76","doi-asserted-by":"publisher","first-page":"102328","DOI":"10.1016\/j.redox.2022.102328","article-title":"AKAP12 ameliorates liver injury via targeting PI3K\/AKT\/PCSK6 pathway","volume":"53","author":"Wu","year":"2022","journal-title":"Redox Biol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12967-024-06047-0","article-title":"An integrative analysis reveals cancer risk associated with artificial sweeteners","volume":"23","author":"Xie","year":"2025","journal-title":"J. Transl. Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"10384","DOI":"10.1038\/s41598-025-94947-6","article-title":"Analysis and comparison of adverse events of colistin administered by different routes based on the FAERS database","volume":"15","author":"Xu","year":"2025","journal-title":"Sci. Rep."},{"key":"B79","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/nmeth.3484","article-title":"Phenolyzer: phenotype-based prioritization of candidate genes for human diseases","volume":"12","author":"Yang","year":"2015","journal-title":"Nat. Methods"},{"key":"B80","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41591-019-0709-7","article-title":"High-resolution mycobiota analysis reveals dynamic intestinal translocation preceding invasive candidiasis","volume":"26","author":"Zhai","year":"2020","journal-title":"Nat. Med."},{"key":"B81","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41419-018-0514-0","article-title":"ZBTB20 regulates EGFR expression and hepatocyte proliferation in mouse liver regeneration","volume":"9","author":"Zhang","year":"2018","journal-title":"Cell Death Dis."},{"key":"B82","doi-asserted-by":"publisher","first-page":"103323","DOI":"10.1016\/j.redox.2024.103323","article-title":"Tryptanthrin targets GSTP1 to induce senescence and increases the susceptibility to apoptosis by senolytics in liver cancer cells","volume":"76","author":"Zhang","year":"2024","journal-title":"Redox Biol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"741","DOI":"10.3892\/mmr.2021.12381","article-title":"Protective effect of carvacrol on liver injury in type 2 diabetic db\/db mice","volume":"24","author":"Zhao","year":"2021","journal-title":"Mol. Med. Rep."},{"key":"B84","doi-asserted-by":"publisher","first-page":"103200","DOI":"10.1016\/j.etap.2019.103200","article-title":"Bioinformatic and experimental data decipher the pharmacological targets and mechanisms of plumbagin against hepatocellular carcinoma","volume":"70","author":"Zhou","year":"2019","journal-title":"Environ. Toxicol. Pharmacol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"891336","DOI":"10.3389\/fphar.2022.891336","article-title":"Antifungal drugs and drug-induced liver injury: a real-world Study leveraging the FDA adverse event reporting system database","volume":"13","author":"Zhou","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1392914","DOI":"10.3389\/fphar.2024.1392914","article-title":"A disproportionality analysis of adverse events caused by GnRHas from the FAERS and JADER databases","volume":"15","author":"Zou","year":"2024","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1632488\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T05:35:51Z","timestamp":1755063351000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1632488\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":84,"alternative-id":["10.3389\/fphar.2025.1632488"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1632488","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,13]]},"article-number":"1632488"}}